Study of Low-Dose Antiplatelet Medications With or Without Antioxidants for Dry Age-Related Macular Degeneration in Adults Aged 50 to 85

What this Trial Is About

This research aims to evaluate the effects of low doses of antiplatelet medications, such as aspirin 81 mgday or clopidogrel 75 mgday, with or without the addition of antioxidants N-acetylcysteine 600 mgday in patients with dry age-related macular degeneration AMD who have large drusen. The study will include participants aged 50 to 85 years and is sponsored by Navamindradhiraj University. It is a Phase 3, non-randomized, interventional clinical trial focused on understanding how these treatments may influence drusen progression. Participants will be divided into three groups those already taking low-dose antiplatelet medications, those who will take antiplatelet drugs combined with antioxidants as prescribed by the investigator, and those who do not use any medication. The antiplatelet medications studied include aspirin and clopidogrel, both taken daily, and the antioxidant used is N-acetylcysteine, also taken daily. The trial will monitor participants over one year. During the study, participants will undergo evaluations including drusen volume analysis, best-corrected visual acuity testing, and assessments of disease progression and side effects from medication intake. These measurements will be taken over a 1-year period to assess the impact of the treatments. The trial does not involve masking or blinding, and participants will be monitored for safety and treatment effects throughout the study duration.

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study